CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $23.61M, above the global median of $18.73M
- FinancialsAltman Z-Score 6.12: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.17%Above 5Y avg (1.11%)
Annual Rate
CNY 0.35Paid annual
Payout Ratio
0.0%Sustainable
Payback Period
91.7 yr
Last Ex-Dividend
Jul 8, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.76BCNY710.69M · vs all stocks (USD)
Trailing P/E
26.92xvs Biotechnology peers
Revenue (TTM)
917.05MCNY136.94M · vs all stocks (USD)
Profit Margin
18.61%vs Biotechnology peers
Beta
0.3950xvs all stocks
52-Week Change
-43.03%vs all stocks
Market Capitalization
4.76BCNY710.69M · vs all stocks (USD)
Enterprise Value
4.27BCNY637.31M · vs all stocks (USD)
Trailing P/E
26.92xvs Biotechnology peers
Price to Sales (TTM)
4.99xvs Biotechnology peers
Price to Book (MRQ)
1.42xvs Biotechnology peers
Enterprise to Revenue
4.65xvs Biotechnology peers
Enterprise to EBITDA
19.64xvs Biotechnology peers
Gross Margin
89.81%vs Biotechnology peers
Profit Margin
18.61%vs Biotechnology peers
Operating Margin
21.65%vs Biotechnology peers
Return on Assets (TTM)
2.90%vs Biotechnology peers
Return on Equity (TTM)
5.05%vs Biotechnology peers
Revenue (TTM)
917.05MCNY136.94M · vs all stocks (USD)
Revenue per Share (TTM)
5.80CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-0.40%vs Biotechnology peers
Gross Profit (TTM)
822.88MCNY122.88M · vs all stocks (USD)
EBITDA (TTM)
206.63MCNY30.86M · vs all stocks (USD)
Net Income (TTM)
170.64MCNY25.48M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
4.20%vs Biotechnology peers
Operating Cash Flow (TTM)
131.91MCNY19.70M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
158.09MCNY23.61M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.3500CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
1.17%vs all stocks
5-Year Average Dividend Yield
1.11%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
285.21MCNYFY2025 · Dec 31, 2025Revenue
915.12MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
92.25MCNYFY2025 · Dec 31, 2025Gross Profit
822.87MCNYFY2025 · Dec 31, 2025Operating Income
198.58MCNY29.65M · vs all stocks (USD)
Pre-tax Income
189.69MCNYFY2025 · Dec 31, 2025Income Tax Expense
20.26MCNYFY2025 · Dec 31, 2025Net Income
169.42MCNYFY2025 · Dec 31, 2025EBIT
197.22MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
244.31MCNYFY2025 · Dec 31, 2025Research & Development
51.86MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
327.05MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.79MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
8.99MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
7.53MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.05CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.04CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
158.06MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
158.06MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
169.42MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-3.46MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
140.81MCNYFY2025 · Dec 31, 2025Free Cash Flow
87.97MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
332.57MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
169.42MCNYFY2025 · Dec 31, 2025Other Non-cash Items
7.70MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-62.36MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
26.06MCNYFY2025 · Dec 31, 2025Capital Expenditures
-52.84MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.12BCNYFY2025 · Dec 31, 2025Sale of Investments
1.21BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
44.29MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
298.87MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-180.46MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-102.39MCNYFY2025 · Dec 31, 2025Other Financing Charges
-33.37MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-17.35MCNYFY2025 · Dec 31, 2025Shares Outstanding
159.01MSharesUpdated Sep 22, 2026Float Shares
80.70MSharesUpdated Sep 22, 2026% Held by Insiders
49.31%vs all stocks
% Held by Institutions
5.61%vs all stocks
Total Cash (MRQ)
921.09MCNY137.55M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.87CNYUpdated Sep 22, 2026Total Debt (MRQ)
376.90MCNY56.28M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1085xvs Biotechnology peers
Current Ratio (MRQ)
2.55xvs Biotechnology peers
Book Value per Share (MRQ)
20.28CNYUpdated Sep 22, 2026Total Assets
4.09BCNY611.51M · vs all stocks (USD)
Total Current Assets
1.40BCNYFY2025 · Dec 31, 2025Total Liabilities
598.51MCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.70BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
139.06MCNYFY2025 · Dec 31, 2025Total Current Liabilities
459.45MCNYFY2025 · Dec 31, 2025Cash
295.85MCNYFY2025 · Dec 31, 2025Cash Equivalents
36.73MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
332.57MCNYFY2025 · Dec 31, 2025Other Short-term Investments
500.43MCNYFY2025 · Dec 31, 2025Accounts Receivable
272.30MCNYFY2025 · Dec 31, 2025Inventory
54.47MCNYFY2025 · Dec 31, 2025Accounts Payable
31.20MCNYFY2025 · Dec 31, 2025Short-term Debt
262.70MCNYFY2025 · Dec 31, 2025Other Current Liabilities
50.14MCNYFY2025 · Dec 31, 2025Long-term Debt
57.46MCNYFY2025 · Dec 31, 2025Common Stock (Book)
159.01MCNYFY2025 · Dec 31, 2025Retained Earnings
2.04BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.50BCNY522.13M · vs all stocks (USD)
Treasury Stock
32.86MCNYFY2025 · Dec 31, 202552-Week Low
27.33CNYUpdated Sep 22, 202652-Week High
57.50CNYUpdated Sep 22, 202652-Week Change
-43.03%vs all stocks
Beta
0.3950xvs all stocks
50-Day MA
31.50CNYUpdated Sep 22, 2026200-Day MA
36.11CNYUpdated Sep 22, 2026Avg 10-Day Volume
1.33MSharesUpdated Sep 22, 2026Avg 30-Day Volume
2.63MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
1.07CNYUpdated Sep 22, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.12: safe zoneNotable
Altman Z-Score: 6.12
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $23.61M, above the global median of $18.73MNotable
Levered free cash flow (USD): 23,607,261.926Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Lifotronic Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yabao Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Knight Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sanyou Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Morepen Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhongzhu Healthcare Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Beilu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wave Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Henan Splendor Science & Technology Co., Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityIndustry-Benchmarked ROA and Margin Elevated
Texas Pacific Land Corporation
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityIndustry-Benchmarked ROA and Margin Elevated
Classys Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityIndustry-Benchmarked ROA and Margin Elevated